What is IRON's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.38B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IRON?

P/E (TTM) is n/a and 52-week range is $40.00 to $99.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IRON figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IRON?

The company profile lists net income (TTM) near $-251M, EPS (TTM) near $-6.57 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Disc Medicine Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Watertown, Massachusetts, US, 38.2M shares outstanding, ISIN US2546041011 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Disc Medicine Inc

$IRON

Health Care · Biotechnology

IR Run Scenarios

$62.06

+2.12%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Employees

154

Website

www.discmedicine.com/

IPO

2020-08-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)